NCT01428284View on ClinicalTrials.gov

A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Healthy
Interventions
DRUG

Canagliflozin/Probenecid

Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Probenicid: Type = 1, unit = mg, number = 500, form = tablet, route = oral use. One 300-mg canagliflozin tablet taken orally once daily on Days 1 to 14 (administration of canagliflozin alone) and on Days 15 to 17 (administration of canagliflozin + twice-daily administration of probenecid).

Trial Locations (1)

Unknown

Overland Park

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT01428284 - A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers | Biotech Hunter | Biotech Hunter